



Scale Biosciences Announces New Commercial Hires to Support Continued Growth

SAN DIEGO, CALIF.- April 8, 2024 - Scale Biosciences (ScaleBio™), an innovator in single cell sequencing, today announced new appointments to its commercial team, including the appointment of new sales and support leader Kim Ferguson as Vice President of Global Sales and Support. Collectively, the appointments reflect the maturation of Scale Bio, which now offers a range of solutions for single cell omics research studying single cell RNA, single cell methylation, CRISPR guide enrichment, and more.

“Bringing together a robust and experienced team of sales and support professionals under Kim Ferguson’s leadership will enable ScaleBio to accelerate our growth and partner with a larger base of global customers,” said Giovanna Prout, CEO of ScaleBio. “We’ve recruited a world-class team with decades of experience supporting research, biotech, and pharma customers around the world and across a wide range of genomics applications.”

Kim Ferguson has led a remarkable career spanning multiple high-profile companies, where she drove revenue growth and sales. Prior to joining ScaleBio, Kim served as Vice President of Global Sales Operations at DNA Script where she validated target customers and product specs pre-commercial launch and developed a sales pipeline and commercial operations functions to enable sale execution. Previously, she held a variety of sales and scientific roles at Illumina, Eppendorf, VWR International, Orthologic Corp., and Natick Soldier Center. Kim received her B.S. in Biology and Biotechnology and M.S. in Biology from Worcester Polytechnic Institute.

“Single cell omics technologies have the potential to dramatically expand biological research and accelerate discovery. ScaleBio’s products and services offer the research community a new set of accessible tools to facilitate a broad range of programs,” said Kim Ferguson. “I look forward to working with the expanding ScaleBio commercial team to support customers pushing the boundaries of science to better understand biology at single cell resolution.”

Other new additions to the commercial team include Sheila Clark, Director of Commercial Marketing, Ravi Girdhar, Head of EMEA Sales and Support, as well as new sales representatives and field application scientists. The company plans to continue to grow the commercial function in the coming months with additional marketing, sales, and support representatives.

To learn more about Scale Bio, visit www.scale.bio or visit <https://jobs.lever.co/ScaleBio> to view open career opportunities.

About Scale Biosciences

ScaleBio is a single cell sequencing solutions company founded by a multidisciplinary team of scientists and technologists with combined expertise in next-generation sequencing, genomics, proteomics, and bioinformatics, and a common mission for unlocking the potential of single cell analysis at scale by eliminating barriers to discovery. ScaleBio is financed by leading life sciences tools investors ARCH Venture Partners, BNG and Tao Capital. ScaleBio has R&D facilities in San Diego and San Carlos, Calif.

Contacts

For Media

Gwen Gordon

gwen@gwengordonpr.com

For General Inquiries

info@scale.bio